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Abstract
Background: Carcinoma of uterine cervix is the second most common cancers among women worldwide. Combined
radiation and chemotherapy is the choice of treatment for advanced stages of the disease. The prognosis is poor, with a
five-year survival rate ranging from about 20–65%, depending on stage of the disease. Therefore, genetic characterization
is essential for understanding the biology and clinical heterogeneity in cervical cancer (CC).
Methods: We used a genome-wide screening method – comparative genomic hybridization (CGH) to identify DNA
copy number changes in 77 patients with cervical cancer. We applied categorical and survival analyses to analyze whether
chromosomal changes were related to clinico-pathologic characteristics and patients survival.
Results: The CGH analysis revealed a loss of 2q33-q37 (57.1%), gain of 3q (54.5%) and chromosomal amplifications
(20.77%) as frequent genetic changes. A total of 15 amplified chromosomal sites were detected in 16 cases that include
1p31, 2q32, 7q22, 8q21.2-q24, 9p22, 10q21, 10q24, 11q13, 11q21, 12q15, 14q12, 17p11.2, 17q22, 18p11.2, and 19q13.1.
Recurrent amplified sites were noted at 11q13, 11q21, and 19q13.1. The genomic alterations were further evaluated for
prognostic significance in CC patients, and we did not find any correlation with a number of clinical or histological
parameters. The tumors harboring HPV18 exhibited higher genomic instability compared to tumors with HPV 16.
Conclusions:  This study demonstrated that 2q33-q37 deletions, 3q gains and chromosomal amplifications as
characteristic changes in invasive CC. These genetic alterations will aid in the identification of novel tumor suppressor
gene(s) at 2q33-q37 and oncogenes at amplified chromosomal sites. Molecular characterization of these chromosomal
changes utilizing the current genomic technologies will provide new insights into the biology and clinical behavior of CC.
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Background
Cervical Cancer (CC) is the second most common malig-
nancy among women in both incidence and mortality [1].
The HPV infection has been implicated as the most
important etiologic factor in the development of CC [2].
Although 95% of the patients with precancerous lesions
harbor HPV, only a small fraction of the cases eventually
progress to invasive cancer [3]. Therefore, HPV infection
alone was considered insufficient for the malignant con-
version suggesting role of other genetic changes in the
development of CC. Further identification of such genetic
alterations is critical in our understanding of the molecu-
lar basis of CC development.
Although cytogenetic studies on CC have identified a
number of non-random karyotypic changes involving
chromosomes 1, 3, 5, 17, and X [4], the search for the crit-
ical cytogenetic changes has been hampered by technical
difficulties in culturing tumor cells and inherent karyo-
typic complexity in this tumor. Therefore, the conven-
tional karyotype analyses have not provided definite clues
on the genetic alterations involved in CC. The advent of
CGH has opened a novel means of characterizing
genomic imbalances in the tumor genome [5,6]. To date,
a number of CGH studies have identified chromosomal
changes involving loss of 2q, 3p, 4p, 4q, 5q, 6q, 11q, 13q
and 18q regions and gain of 1q, 3q, 5p and 8q at various
stages of CC [7-14]. All these studies have commonly
identified 3q gain, which occurred at severe dysplasia/car-
cinoma-in-situ leading to a suggestion that this genetic
aberration plays a pivotal role in the transition from dys-
plasia to invasive CC [7]. A number of molecular genetic
studies also have been attempted to define the genetic
alterations and found frequent LOH at 3p, 4p, 4q, 5p, 6p,
6q, 11q and 17p chromosomal regions suggesting the
presence of putative tumor suppressor genes on these
chromosomes [4,15-19]. Despite this cytogenetic and
molecular characterization of cervical precancerous and
cancerous lesions, the genetic basis of CC development
and progression remains poorly understood.
Here we report CGH characterization of chromosome
copy number alterations on a panel consists of 77 CC and
we identified 2q33-q37 deletions, 3q gains and chromo-
somal amplifications as the frequent genetic changes.
Methods
Tumor Specimens
A total of 77 tumor tissues were obtained from patients
treated at the Instituto Nacional de Cancerologia, Bogota,
Colombia and the Department of Obstetrics and Gynecol-
ogy of Friedrich Schiller University, Jena, Germany. Of
these, 5 were diagnosed as adenocarcinoma and the
remaining 72 were as squamous cell carcinoma. Based on
the International Federation of Gynecology and Obstet-
rics (FIGO) criteria, the tumors classified as 14 stage IB, 18
stage IIB, 42 stage IIIB, and three stage IVB patients. All the
tumors were positive for high-risk HPV types, except two
(CC81 and CC148). All the biopsies were estimated to
contain more than 60% of tumor cells. Clinical informa-
tion such as age, stage and size of the tumor, follow-up
data after treatment was collected from the review of insti-
tutional medical records, and by contacting outside phy-
sicians and institutions. All 77 tumors were followed up
between one to 72 months after treatment. HPV types
were identified as described earlier [20].
Comparative Genomic Hybridization
High-molecular weight DNA was isolated from frozen
tumors and normal placenta by standard methods. The
CGH was performed as described previously [5]. Briefly,
the tumor and normal DNAs were labeled by nick-trans-
lation with fluorescein-12-dUTP and Texas Red-5-dUTP
(NEN-DuPont, Boston, MA), respectively. Equal amounts
of tumor and normal DNA were co-precipitated along
with human Cot-1 DNA (GIBCO/BRL, Gaithersburg, MD)
and re-suspended in the hybridization buffer before
hybridization to metaphase chromosomes prepared from
phytohemagglutinin-stimulated lymphocyte cultures
from normal individuals. Upon hybridization, the chro-
mosomes were counter-stained with DAPI to allow their
identification. Seven to 10 metaphases were captured for
each case using a cooled charge-coupled device (CCD)
camera attached to a Nikon Eclipse 800 microscope. The
metaphase preparations were processed using the Quanti-
tative Image Processing System (Applied Imaging, Santa
Clara, CA). Red, green, and blue fluorescence intensities
were analyzed for all metaphases, normalized to a stand-
ard length, and statistically combined to show the
red:green signal ratio and 95% confidence intervals for
the entire chromosome. Copy number changes were
detected based on the variance of the red: green ratio pro-
file from the standard of 1. Ratio values of 1.20 and 0.80
were used as upper and lower thresholds to define gains
and losses, respectively. High-level amplification was
defined as occurrence of fluorescein intensity values in
excess of 2.0 along with a strong localized FITC (fluores-
cein isothiocynate) signal at the chromosomal site. For
assignment of high-level amplification to a chromosomal
band, the peak ratio profiles were compared to the corre-
sponding DAPI banding of individual chromosomes.
Statistical Analysis
We used categorical and survival analyses to analyze
whether chromosomal changes were related to clinico-
pathologic characteristics and patients survival. We first
categorized chromosomal changes into any amplification,
loss of 2q, 3q gain, and individual gains and losses. The
associations between these changes and different clinico-
pathologic characteristics including histological type,BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/5
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stage, size of the tumor, patient's age, HPV type, and treat-
ment response were assessed through Chi-Square [21]
and Fisher's Exact tests [22]. Given the number of compar-
isons that we made, all p values were adjusted for multiple
comparisons using The False Discovery Rate method [23].
Total losses, total gains, and total changes identified in all
chromosomes were treated as continuous variables and
Analysis of Variance was performed to compare the mean
losses, gains and changes among different clinico-patho-
logic groups [21]. Cox Proportional Hazard Models were
further applied to assess the relative hazard (risk) of dying
associated with chromosomal changes after adjusting for
subject's age at diagnosis, stage and size of the tumor and
HPV type [24].
Results and Discussion
Genomic DNA from 77 primary cervical carcinomas was
subjected to CGH to identify chromosomal copy number
changes. We previously reported CGH data on 44 primary
tumors and the remaining 33 cases were added to this
study [25]. Seventy-five of the 77 (97.4%) tumors were
positive for HPV DNA. The remaining two tumors were
HPV negative. HPV16 was found in 45 (60%) tumors,
HPV18 in 4 (5.3%), while multiple HPV infections and
other types of HPV were found in 26 (34.7%) tumors
(Table 3).
Chromosome 2q33-q36 deletions and gain of 3q26-q29 are 
the most common genetic changes in CC
Under representation of DNA copy number (>25%) was
noted at seven chromosomal regions: 2q (57.1%), 13q
(42.9%), 4q (36.4%), 11q (36.4%), 4p (29.9%), 17p
(29.9%), and 3p (28.6%). Chromosomal gains (>15%)
were identified in 11 chromosomal arms: 3q (54.5%), 5p
(29.9%), 1p (27.3%), 8q (26%), 20q (26%), 9q (24.7%),
1q (19.5%), 20p (18.2%), Xq (16.9%), 19p (16.9%), and
13q (15.6%) (Figure 1). The common regions of deletions
on chromosomes 2q were mapped to 2q22-q33 and
2q36-q37, 13q deletions at 13q12-q13 and 13q22-q34,
and 11q deletions at 11q23-q25. The common region of
gained sites was identified for 8q at 8q23-q24, 1p at 1p32-
p36, and for 13q at 13q22-q34.
A very striking observation in the present study was the
loss of 2q in 57.1% of CC. The common regions of dele-
tions were mapped to 2q22-q33 and 2q36q37 regions.
Previous CGH and LOH studies have noted low frequency
of genetic losses at 2q in precancerous lesions, carcinoma-
in-situ, and invasive CC [8,9,12,15]. This might be due to
limited number of tumors analyzed and lack of systematic
analysis. This region also affected by the deletion in a
number of other tumor types and has been shown to pre-
dict poor prognosis at the advanced stages of disease [26].
Our extensive LOH analysis of 2q35-q37.1 regions has
identified two distinct minimal deletions at 2q35-q36.1
and 2q36.3-q37.1 in precancerous and invasive lesions
[25]. A number of genes (CFLAR, CASP10 and PPP1R7)
mapped to these regions were found to be down regulated
and this down-regulation was reactivated upon exposure
to demethylating and histone deacetylase inhibiting
agents. These data suggest that both genetic epigenetic
changes play a role in 2q alterations [25,27]. Thus, the
identification of high incidence of 2q33-q36 losses in CC
strongly suggests that this region harbor one or more
tumor suppressor genes. Other frequently deleted chro-
mosomal regions that we have identified, such as 3p, 4p,
4q, 11q, and 17p, also have been previously reported to
contain high frequency of LOH [15,16,27,28].
Of the DNA copy number gains seen in CC, the 3q exhib-
ited highest frequency in 54.5% of tumors. Although most
tumors showed complete 3q gain, a common region of
gain mapped to 3q26-q29, which is identical to previ-
ously reported studies [7,8]. In CC, the gain of 3q has
been shown to associate with progression from high grade
CIN to invasive cancer [7]. A number of studies have iden-
tified candidate genes on 3q26-q27 regions. The PIK3CA,
which encodes a catalytic subunit of phosphatidylinsitol
3-kinase, has been implicated as a candidate oncogene at
3q26 in carcinomas of cervix, ovary and head and neck
[29-31]. Although other genes such as eIF-5A2  and
CCNL1 have been recently implicated as candidate onco-
genes of 3q amplification, it is still unclear regarding the
target of amplified genes on 3q [32,33].
Chromosomal amplification is a frequent phenomenon in 
CC
We identified 18 high-level chromosomal amplifications
at 15 different chromosomal sites in 16 of 77 (20.77%)
cases studied. The amplifications were noted at 1p31,
2q32, 7q22, 8q21.2-q24, 9p22, 10q21, 10q24, 11q13,
11q21, 12q15, 14q12, 17p11.2, 17q22, 18p11.2, and
19q13.1 (Figure 2). Recurrent sites of amplification were
noted in 3 chromosomal sites at 11q13 (CC52 and T-
130), 11q21 (CC98 and CC117), and 19q13.1 (T-132
and T-146).
Increase in gene dosage by DNA amplification is a com-
mon mechanism to achieve over-expression of genes in
tumors. Gene amplification has been shown to
commonly associate with tumor progression, chemother-
apy resistance and clinical outcome in a variety of tumor
types [34]. The CGH technology has particularly aided in
identifying amplifications of chromosomal loci and the
subsequent identification of the target genes in a number
of tumor types [5,6]. However, the scope of gene and
chromosomal amplifications has been limited in CC. In
the present study, we identified a very high frequency of
amplified chromosomal sites in CC. We have previously
reported similar high frequency of chromosomal amplifi-BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/5
Page 4 of 9
(page number not for citation purposes)
Ideogram showing DNA copy number changes identified by CGH in 77 primary CC Figure 1
Ideogram showing DNA copy number changes identified by CGH in 77 primary CC. Thin vertical lines on either side of the 
ideogram indicate losses (red) and gains (green) of chromosomal region. The chromosomal regions of the high level amplifica-
tion were shown in thick lines (right). Total number of the same chromosomal aberration was shown as number next to the 
ideogram.
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Chromosomal amplifications identified by CGH in CC Figure 2
Chromosomal amplifications identified by CGH in CC. Partial CGH karyotypes (left) and corresponding ratio profiles (right) 
illustrating 15 amplified chromosomal regions in CC. The blue line in the ratio profiles represents the mean of 8 to 10 chromo-
somes, and the yellow lines indicate the standard deviation. The vertical red and green bars on the left and right of the ideo-
gram indicate threshold values of 0.80 and 1.20 for loss and gain, respectively. A threshold value of 2.0 or more indicates 
amplifications.BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/5
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cations in 7 of 8 CC cell lines [35]. Several of these sites
are of interest namely 8q24, which harbor the MYC gene
and was previously shown as a candidate amplified gene
in CC by Southern blot analysis [36]. A recently identified
protein tyrosine phosphatase (PRL-3) gene also maps to
8q24 and was shown to express at high levels in metastatic
colon cancer [37]. Also WISP, a member of the family of
cysteine-rich, glycosylated signaling proteins that mediate
cell proliferation, adhesion, cell polarity and cell fate,
maps to 8q24 and has been shown to over-express in
colon cancer [38]. The amplified CCND1/PRAD1 gene on
11q13 has been shown to be over expressed in CC cell
lines [39]. Thus, the identification of a number of chro-
mosomal regions of amplification in the present study
suggests that the gene amplification is a common genetic
alteration in invasive CC. Further molecular characteriza-
tion of the amplified regions should facilitate the identifi-
cation of the target amplified genes in CC.
Correlation of chromosomal changes with clinico-
pathologic parameters
The clinical behavior of the CC is highly unpredictable.
There are currently no molecular genetic markers of out-
come used for CC that distinguishes tumor in terms of its
treatment response. In the present study we found a
number of non-random genetic changes in invasive CC.
We made an attempt to correlate the genetic losses, gains
and amplifications with clinico-pathologic features such
as age, stage and size of the tumor, clinical outcome, and
HPV type (Table 1 & Table 2).
The total number of genetic changes combining losses
and gains together, total gains alone, total losses alone,
and individual gains and losses showing in >15% cases,
and chromosomal amplifications were subjected to uni-
variate analysis examining the associations. No correla-
tion was found with any of the parameters examined,
except HPV18 (Table 1). The patients that had HPV18
infection showed higher frequency of chromosomal
amplifications (75% in HPV18 vs. 16.9% in other HPV
types), total losses (10.00 ± 5.48 in HPV18 vs. 4.62 ± 3.49
in HPV 16) and gains (8.75 ± 6.06 in HPV18 vs. 3.33 ±
2.85 in HPV 16) and total changes (18.75 ± 11.53 in
HPV18 vs. 7.96 ± 5.68 in HPV 16) (Table 1). The associa-
tion of genomic instability represented by chromosomal
amplification and copy number changes with HPV18
infection is interesting in the light of the oncogenic poten-
tial of this HPV type. HPV18 is known to cause rapid tran-
sition to malignancy and HPV18-infected tumors are
Table 1: Correlation of chromosomal changes with clinical and histologic paramaters, and HPV status in CC patients
Characteristics Amplification Loss of 2q Gain of 3q Total losses (mean ± s.d.) Total gains (mean ± s.d.) Total changes 
(mean ± s.d.)
Histology
SCC (N = 72) 14 42 41 4.71 ± 3.64 3.93 ± 3.22 8.64 ± 6.31
AC (N = 5) 1 2 1 5.80 ± 3.63 3.20 ± 3.77 9.00 ± 7.11
Significance p = 1.00 p = 0.65 p = 0.17 p = 0.52 p = 0.63 p = 0.90
Stage
I (N = 14) 1 8 6 5.00 ± 3.57 3.71 ± 2.95 8.71 ± 6.08
II (N = 18) 4 12 13 5.11 ± 3.80 3.94 ± 2.84 9.06 ± 6.16
III-IV (N = 45) 10 24 20 4.58 ± 3.65 3.91 ± 3.52 8.49 ± 6.57
Significance p = 0.45 p = 0.63 p = 0.20 p = 0.85 p = 0.98 p = 0.95
Size of tumor
1–5 cm (N = 29) 6 20 15 5.62 ± 4.02 4.10 ± 3.26 9.72 ± 6.84
≥6 cm (N = 38) 6 18 20 4.18 ± 3.52 4.05 ± 3.48 8.24 ± 6.40
Significance p = 0.60 p = 0.08 p = 0.94 p = 0.12 p = 0.95 p = 0.36
Age (yrs)
≤40 (N = 31) 8 21 16 4.58 ± 3.67 3.58 ± 2.67 8.16 ± 5.78
41–60 (N = 28) 5 12 13 5.39 ± 3.73 4.32 ± 3.37 9.71 ± 6.55
≥60 (N = 18) 2 11 13 4.17 ± 3.47 3.72 ± 3.95 7.89 ± 6.93
Significance p = 0.44 p = 0.14 p = 0.13 p = 0.50 p = 0.67 p = 0.54
HPV type
HPV16 (N = 45) 7 27 26 4.62 ± 3.49 3.33 ± 2.85 7.96 ± 5.68
HPV18 (N = 4) 3 3 3 10.00 ± 5.48 8.75 ± 6.06 18.75 ± 11.53
Multiple (N = 10) 3 4 2 4.40 ± 2.37 4.10 ± 2.96 8.50 ± 4.74
Others (N = 16) 2 9 10 3.94 ± 3.00 3.81 ± 2.71 7.75 ± 5.11
Significance p = 0.04 p = 0.11 p = 0.02 p = 0.01 p = 0.01
Treatment response
CR (N= 34) 5 21 21 4.91 ± 3.78 3.79 ± 3.46 8.71 ± 6.67
DOD/PR (N = 43) 10 23 21 4.67 ± 3.54 3.95 ± 3.08 8.63 ± 6.09
Significance p = 0.35 p = 0.26 p = 0.78 p = 0.83 p = 0.96
P value corresponds to the P value from Chi-Square test, or from the Fisher's Exact test (where appropriate).BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/5
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generally more aggressive [40]. However, the number of
tumors with HPV18 infection in the present study was
small to come to any definite conclusions.
While we found a number of different genetic changes in
our large study of CC, these changes were not statistically
significantly associated with clinico-pathologic criteria
except for HPV type. Whether the presence of HPV type
influences unique genetic changes needs to be further
explored in a larger study. Given that most CC arises in
women with HPV infection but most women with HPV
infection do not develop CC, uncovering genetic changes
unique to HPV type are critical in understanding CC etiol-
ogy. Studies aimed at elucidating the cellular mechanisms
involved in genomic instability in relation to HPV18 may
better our understanding the underlying biological path-
ways of oncogenic potential of HPV 18.
Contrary to the existing dogma [36,41], the CC patients
with amplification did not show significant correlation
with disease outcome in the present study (Table 1). Fur-
thermore, multivariate survival analysis after adjusting for
age, stage, size of the tumor, and HPV type also did not
show any statistically significant relation to survival
(Table 2). A number of previous studies have shown prog-
nostic value of genomic alterations in CC such as loss of
11p and 18q and over expression of EGFR with poor prog-
nosis, and 9p loss with metastasis [9,41]. However, there
were no reports available on the chromosome amplifica-
tion in relation to prognosis in CC. Gene amplification, in
general, has been shown to predict poor prognosis [42].
However, only few oncogenes have emerged clearly as
indicators of patient prognosis, such as MYCN in neurob-
lastoma and ERBB2 in breast cancer [42]. Although the
chromosomal amplifications identified in the present
study did not predict worse outcome, our work provided
the first evidence towards identifying specific gene(s) at
amplified chromosomal sites that may have clinical
importance in predicting treatment response.
Conclusions
In summary, the present study demonstrated that 2q33-
q37 deletions, 3q gains and chromosomal amplifications
as characteristic changes in invasive CC. The genetic alter-
ations reported here have the potential to uncover novel
tumor suppressor gene(s) at 2q33-q37 and oncogenes at
amplified chromosomal sites. Molecular characterization
of these chromosomal changes utilizing the new genomic
technologies should provide important clues of the
genetic mechanisms of initiation and progression, and
provide new insights into the clinical behavior and man-
agement of CC.
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